Lung Carcinoma Metastatic to the BrainMETAPERFNCT02250755
MRI Perfusion on T1 and T2 Brain Lesion(s)
A study testing MRI T1 T2 sequences in people with Lung Carcinoma Metastatic to the Brain, run by University Hospital, Lille at 1 site in France.
Trial summary
This study therefore aims to assess current treatment recommended by scientific societies [ 6-13 ] , brain MRI with injection of contrast for the diagnosis and monitoring of brain metastases . The recommended dose of this examination gadolinium is from 0.1 to 0.3 mmol / kg [ 14 ] . Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Carcinoma Metastatic to the Brain
- What is being tested?
- MRI T1 T2 sequences
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteFrance
- Study dates
- Jun 2013to Nov 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Major Patients
- Addressed to MRI for initial assessment of brain metastases
- At a suspicion of one or more brain metastases in the brain scanner routine screening
- Followed for lung cancer histologically documented in the Thoracic Oncology Service of Professor Lafitte (contact: Dr Cortot)
- To whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered
- Be socially insured-
Who cannot join
- Absolute contraindication to MRI (pacemaker, implantable pacemaker, metallic foreign body intraorbital)
- Patients minors under guardianship / curatorship
- Patients with impaired judgment skills or unable to receive information
- Pregnant Women
- Patients for which lesions are not compatible with lung metastases
- Patients with brain metastases or already known and explored MRI
- Patients for whom treatment by surgical excision of brain metastases is considered
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of MRI Sequences T1 and T2 * Cerebral Perfusion to Aid in the Diagnosis and Evaluation of Brain Therapeutic Response With Chemotherapy or Targeted Therapy(s) Lesion(s) in Patients Treated and Followed for a Pulmonary Neoplasia
This study therefore aims to assess current treatment recommended by scientific societies [ 6-13 ] , brain MRI with injection of contrast for the diagnosis and monitoring of brain metastases . The recommended dose of this examination gadolinium is from 0.1 to 0.3 mmol / kg [ 14 ] . Sequences infusion different from one center to the other made : some use the infusion T1, other infusion T2 * . No recommendation establishes whether it is preferable to use one or the other of these sequences.
No examination is added for the purposes of protocol. Indications for MRI and the number and timing of MRI checks under this protocol are consistent with what is done in practice . The used type of gadolinium and the injected dose will be identical for both sequences infusion . The assessment shall not in any case the contrast but the interpretation of the sequence itself. Special procedures monitoring implemented embodiment correspond to the two sequences instead of infusion (one of T1-weighted and T2 * in the other ) , in the original MRI and MRI of the first control , in order to compare their effectiveness
Read the detailed description
Eligibility criteria:
- Major Patients
- Addressed MRI for initial assessment of brain metastases
- At a suspicion of one or more brain metastases in the brain scanner routine screening
- Follow for lung cancer histologically documented
- In the Thoracic Oncology Service Professor Lafitte (contact: Dr Cortot)
- To whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered
- Be socially insured
Main Outcomes measures:
Comparing the area under the ROC curve of different parameters evaluated in T1 and T2 * perfusion during the initial assessment for the diagnosis of maximal tumor response evaluated at 1 year
- Conditions
- Lung Carcinoma Metastatic to the Brain
- Being tested
- MRI T1 T2 sequences
- Keywords
- MRI perfusion, therapeutic response, chemotherapy, brain metastases
- Medical subject headings
- Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRI T1 T2 sequencesOther
MRI
| Study group | Role | What they receive |
|---|---|---|
| MRI T1 T2 sequences | Experimental | comparison of perfusion sequences T1 T2 in patients with brain metastase cancer Receives: Other: MRI T1 T2 sequences |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparing different parameters evaluated in T1 and T2 * perfusion
Comparing the area under the ROC curve of different parameters evaluated in T1 and T2 * perfusion during the initial assessment for the diagnosis of maximal tumor
Measured: 3 years
Secondary outcomes (3)
Evaluation tumor response
Comparison of the area under the ROC curve of the change in the first control of the various parameters measured in T1 and T2 * infusion, for the diagnosis of maximum tumor response evaluated at 1 year
Measured: 1 year
Radiological progression-free survival
Comparison of the ability of the two sequences to predict infusion:
Measured: 1 year
Survival without neurological signs
Comparison of the ability of the two sequences to predict infusion:
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2014 (estimated)
- Study startJun 2013
- Primary completionMay 2015
- Study completionNov 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Lung Carcinoma Metastatic to the BrainStudies of the same condition, open and under way.
- More trials run by University Hospital, LilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Lille
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Xavier LECLERC, Professor, Study director, CHRU of Lille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02250755
- Sponsor's protocol ID
- 2012_27
- Other IDs
- 2012-A01644-39
- Acronym
- METAPERF
- Status last verified
- Nov 2015
- First submitted
- 5 Jun 2014
- Last updated
- 22 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
Publications
Kuchcinski G, Le Rhun E, Cortot AB, Drumez E, Duhal R, Lalisse M, Dumont J, Lopes R, Pruvo JP, Leclerc X, Delmaire C. Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer. Eur Radiol. 2017 Sep;27(9):3733-3743. doi: 10.1007/s00330-017-4756-5. Epub 2017 Feb 16.
PubMed 28210799
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of MRI Sequences T1 and T2 * Cerebral Perfusion to Aid in the Diagnosis and Evaluation of Brain Therapeutic Response With Chemotherapy or Targeted Therapy(s) Lesion(s) in Patients Treated and Followed for a Pulmonary Neoplasia
- ClinicalTrials.gov ID
- NCT02250755
- Acronym / sponsor ID
- METAPERF / 2012_27
- Conditions
- Lung Carcinoma Metastatic to the Brain
- Keywords
- MRI perfusion, therapeutic response, chemotherapy, brain metastases
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- University Hospital, LilleUniversity, hospital or other
- Study start
- Jun 2013
- Primary completion
- May 2015 (actual)
- Study completion
- Nov 2015 (actual)
- First posted
- 26 Sep 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study therefore aims to assess current treatment recommended by scientific societies [ 6-13 ] , brain MRI with injection of contrast for the diagnosis and monitoring of brain metastases . The recommended dose of this examination gadolinium is from 0.1 to 0.3 mmol / kg [ 14 ] . Sequences infusion different from one center to the other made : some use the infusion T1, other infusion T2 * . No recommendation establishes whether it is preferable to use one or the other of these sequences.
No examination is added for the purposes of protocol. Indications for MRI and the number and timing of MRI checks under this protocol are consistent with what is done in practice . The used type of gadolinium and the injected dose will be identical for both sequences infusion . The assessment shall not in any case the contrast but the interpretation of the sequence itself. Special procedures monitoring implemented embodiment correspond to the two sequences instead of infusion (one of T1-weighted and T2 * in the other ) , in the original MRI and MRI of the first control , in order to compare their effectiveness
Detailed description
Eligibility criteria:
- Major Patients
- Addressed MRI for initial assessment of brain metastases
- At a suspicion of one or more brain metastases in the brain scanner routine screening
- Follow for lung cancer histologically documented
- In the Thoracic Oncology Service Professor Lafitte (contact: Dr Cortot)
- To whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered
- Be socially insured
Main Outcomes measures:
Comparing the area under the ROC curve of different parameters evaluated in T1 and T2 * perfusion during the initial assessment for the diagnosis of maximal tumor response evaluated at 1 year
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| MRI T1 T2 sequences | Experimental | Other: MRI T1 T2 sequencescomparison of perfusion sequences T1 T2 in patients with brain metastase cancer |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Major Patients
- Addressed to MRI for initial assessment of brain metastases
- At a suspicion of one or more brain metastases in the brain scanner routine screening
- Followed for lung cancer histologically documented in the Thoracic Oncology Service of Professor Lafitte (contact: Dr Cortot)
- To whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered
Key exclusion criteria (7 listed)
- Absolute contraindication to MRI (pacemaker, implantable pacemaker, metallic foreign body intraorbital)
- Patients minors under guardianship / curatorship
- Patients with impaired judgment skills or unable to receive information
- Pregnant Women
- Patients for which lesions are not compatible with lung metastases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRI T1 T2 sequencesMRI | Other | MRI T1 T2 sequences |
Primary outcome
Comparing different parameters evaluated in T1 and T2 * perfusion
Time frame: 3 years
Comparing the area under the ROC curve of different parameters evaluated in T1 and T2 * perfusion during the initial assessment for the diagnosis of maximal tumor
3 secondary outcomes
Evaluation tumor response
Time frame: 1 year
Radiological progression-free survival
Time frame: 1 year
Survival without neurological signs
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2026.
- Results publication: PubMed 28210799Kuchcinski G, Le Rhun E, Cortot AB, Drumez E, Duhal R, Lalisse M, Dumont J, Lopes R, Pruvo JP, Leclerc X, Delmaire C. Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer. Eur Radiol. 2017 Sep;27(9):3733-3743. doi: 10.1007/s00330-017-4756-5. Epub 2017 Feb 16.
Related trials for Lung Carcinoma Metastatic to the Brain
RecruitingPhase 2
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
Non Small Cell Lung Cancer Metastatic
RecruitingPhase 1
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
Active, not recruitingPhase 1
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
Active, not recruitingPhase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Active, not recruitingPhase 3
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xavier LECLERC, Professor study director
CHRU of Lille
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MRI T1 T2 sequences in people with Lung Carcinoma Metastatic to the Brain, run by University Hospital, Lille at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparing different parameters evaluated in T1 and T2 * perfusion (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02250755, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.